• linkedin
  • Increase Font
  • Sharebar

    Top 9 peer-reviewed prostate cancer papers of 2017


    J. Brantley Thrasher, MD, professor of urology, University of Kansas, Kansas City

    Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377:338-51.

    This trial tested the use of abiraterone with ADT versus ADT alone in men with locally advanced or metastatic prostate cancer and showed a significant survival benefit to those receiving abiraterone as first-line therapy in lieu of late in the disease.


    Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med 2017; 376:417-28.

    This trial showed that the addition of 24 months of antiandrogen therapy, in the form of bicalutamide (Casodex) daily, to salvage radiation therapy in men with biochemical recurrence following radical prostatectomy improved long-term survival and lowered the incidence of metastatic disease and death from prostate cancer.

    More from Urology Times:

    Top 5 malpractice articles of 2017

    Biennial vs. annual prostate biopsies: What the data show

    [Quiz]: Voiding symptoms progressing to retention

    To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available